By: Emily MacHale
Tustin, CA - Integrium, LLC announced they will be attending RESI Boston 2017 on September 26th, 2017. RESI allows life science companies to connect with investors that come from different backgrounds related to Virtual Pharma, Angels, Venture Philanthropy, Patient Groups, Corporate Development, and more. With over 800 guests coming from 38 U.S. states and 25 countries, attendees are able to meet and discuss potential opportunities for success for their organizations. Encouraging in person meetings with pharma companies or service providers and investors, RESI is a place for creating new connections, continuing business relationships, and mainly finding capital.
With there being over 1,200 meeting slots and participating as active members in the life sciences community, Integrium is able to share the various funding options that are available within their organization, clinical trial expertise in a number of therapeutic areas, and their platform for CRO and investor success. Integrium prides themselves on helping biotechs of all sizes attain clinical data so they can raise their next round of capital. Therefore, it is important to always be thinking of a key clinical partner that can guide you through the challenges of the drug development process.
Integrium is available for meetings throughout the day on September 26th and welcomes all life sciences companies, investors, and service providers. To schedule a meeting, please contact Emily MacHale at Emily.MacHale@integrium.com or connect with Mike Loftus, Executive Director of Business Development via the RESI partnering system: http://resiboston17.meeting-mojo.com
About Integrium
Integrium helps Micro Cap, Small Cap, and Privately held Biotechs within the New Chemical Entity, 505(b)(2), and Generic space attain clinical data so they can raise the next round of capital. Integrium’s areas of therapeutic focus include Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Secondary specialties include Schedule 2 drugs and Oncology.
Check out our new website!
To learn more about Integrium, contact:
Emily MacHale
Associate Director of Marketing & Research
Emily.MacHale@Integrium.com
908-375-2009
